Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about Phase 3 Trial
Recent news which mentions Phase 3 Trial
< Previous
1
2
3
4
5
6
7
8
9
Next >
Novartis' Lung Cancer Candidate Misses Primary Goal In Post Surgery Setting
August 15, 2022
Tickers
NVS
Tags
News
General
Market News
From
Benzinga
BELLUS Health Announces FDA End-of-Phase 2 Meeting For Refractory Chronic Cough Program
July 12, 2022
Tickers
BLU
Tags
Briefs
Benzinga
BLU
From
Benzinga
Pfizer's Ulcerative Colitis Candidate Shows Remission In Over 30% Of Patients In Pivotal Studies
May 24, 2022
Tickers
PFE
Tags
General
PFE
News
From
Benzinga
Novartis - BeiGene's Tislelizumab Aces Late-Stage Esophageal Cancer Trial
April 27, 2022
Tickers
BGNE
NVS
Tags
Health Care
Movers
BGNE
From
Benzinga
Ampio Pharma Shares Fall As FDA Rejects Proposed Change In Knee Osteoarthritis Trial
April 21, 2022
Tickers
AMPE
Tags
News
General
Phase 3 Trial
From
Benzinga
BeiGene Shares Updated Data From Tislelizumab Combo Trial In Head & Neck Cancer
April 19, 2022
Tickers
BGNE
Tags
General
News
Market News
From
Benzinga
Aeglea Bio Stock Gains On Additional Pegzilarginase Data For Rare Metabolic Disease
April 12, 2022
Tickers
AGLE
Tags
General
News
Penny Stocks
From
Benzinga
Bristol Myers' Neoadjuvant Opdivo/Chemo Improves Event-Free Survival In Early-Stage Lung Cancer Patients
April 11, 2022
Tickers
BMY
Tags
Non/Small Cell Lung Cancer
Briefs
Phase 3 Trial
From
Benzinga
Eli Lilly Reveals More Phase 3 Data From Lebrikizumab Trial In Atopic Dermatitis
April 11, 2022
Tickers
LLY
Tags
Biotech
Benzinga
Large Cap
From
Benzinga
Veru's Stock Nearly Triples As COVID-19 Drugs Cuts Reduces Deaths By 55% In Hospitalized Patients
April 11, 2022
Tickers
VERU
Tags
Biotech
why it's moving
Benzinga
From
Benzinga
Tonix Pharma Starts New Pivotal Trial For TNX-102 SL In Fibromyalgia Patients
April 07, 2022
Tickers
TNXP
Tags
General
News
Market News
From
Benzinga
Vaxxinity Receives $9.25M Funding From CEPI To Support Pivotal COVID-19 Vaccine Trial
April 07, 2022
Tickers
VAXX
Tags
Penny Stocks
Phase 3 Trial
News
From
Benzinga
Biophytis Shares Fall As It Stops Enrollment In Sarconeos COVID-19 Trial, Data Expected In Q3 2022
April 07, 2022
Tickers
BPTS
Tags
Market News
Movers
Health Care
From
Benzinga
Citius Pharma Reveals Topline Immunotherapy Data From Late-Stage Lymphoma Trial
April 06, 2022
Tickers
CTXR
Tags
Phase 3 Trial
Penny Stocks
News
From
Benzinga
AstraZeneca's Ultomiris Shows Sustained Improvements In Functional Activities In Neuromuscular Disease
April 06, 2022
Tickers
AZN
AZNCF
Tags
Biotech
Benzinga
Health Care
From
Benzinga
Novartis Highlights Four-Year Efficacy, Safety Data On Kesimpta In Multiple Sclerosis
April 05, 2022
Tickers
NVS
Tags
Biotech
NVS
Benzinga
From
Benzinga
Theravance Biopharma's Ampreloxetine Shows Benefit In Atrophy Patients, But Not In Parkinson's
April 05, 2022
Tickers
TBPH
Tags
Small Cap
News
General
From
Benzinga
Argenx's Vyvgart Long-Term Treatment Shows Improved gMG Disease Scores
April 05, 2022
Tickers
ARGX
Tags
Phase 3 Trial
Health Care
Market News
From
Benzinga
Lexicon Touts New Favorable Data On Sotaglifozin Cardio Data
April 04, 2022
Tickers
LXRX
Tags
Biotechnology
Biotech
Benzinga
From
Benzinga
Merck - Ridgeback's COVID-19 Antiviral Shows Rapid Elimination Of Infectious SARS-CoV-2 Than Placebo
April 01, 2022
Tickers
MRK
Tags
Biotech
Benzinga
Briefs
From
Benzinga
Sorrento To Start Late-Stage Trial Of Abivertinib In Critically-Ill COVID-19 Patients
March 31, 2022
Tickers
SRNE
Tags
Briefs
SRNE
News
From
Benzinga
InflaRx Shares Plunge After Disappointing Results On Vilobelimab In Critically Ill COVID-19 Patients
March 31, 2022
Tickers
IFRX
Tags
Trading Ideas
Briefs
News
From
Benzinga
Roche's Tiragolumab Immunotherapy Flunks In Late-Stage Lung Cancer Trial
March 30, 2022
Tickers
RHHBF
RHHBY
RHHVF
Tags
Market News
RHHVF
Phase 3 Trial
From
Benzinga
Incyte-Lilly's Olumiant Continue To Show Improved Scalp, Eyebrows, Eyelash Hair Regrowth At 52 Weeks
March 28, 2022
Tickers
INCY
LLY
Tags
Benzinga
INCY
LLY
From
Benzinga
Roivant' Dermavant Showcases New Long-Term Durability, Tolerability Data For Plaque Psoriasis Candidate
March 25, 2022
Tickers
ROIV
Tags
Market News
Health Care
Phase 3 Trial
From
Benzinga
Celcuity Plans To Start Pivotal Gedatolisib Trial In Breast Cancer In 1H 2022
March 24, 2022
Tickers
CELC
Tags
General
News
Phase 3 Trial
From
Benzinga
AstraZeneca's Imfinzi Flunks In Late-Stage Advanced Cervical Cancer Study
March 24, 2022
Tickers
AZN
AZNCF
Tags
Benzinga
AZN
Biotech
From
Benzinga
Pfizer's Ulcerative Colitis Candidate Aces Late-Stage Study
March 23, 2022
Tickers
PFE
Tags
Benzinga
Biotech
Briefs
From
Benzinga
ObsEva Unveils Additional Efficacy Results for Linzagolix In Endometriosis-Associated Pain
March 22, 2022
Tickers
OBSV
Tags
Biotech
Benzinga
Briefs
From
Benzinga
Tonix Says Fibromyalgia Candidate Failed To Achieve Statistical Significance Over Placebo
March 21, 2022
Tickers
TNXP
Tags
Benzinga
TNXP
Biotech
From
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.